Pontchartrain Cancer Center | Strategic Alliance Partnership

During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.

In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

This article first appeared on The Center for Biosimilars®.

The discussion, "Understanding Biomarkers and the Role They Play in Oncology," came during the Community Oncology Alliance Payer Exchange Summit, held October 23-24 in Reston, Virginia.

Oncologists express concerns about the replacement for the Oncology Care Model; the EOM is set to start July 1, 2023.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discusses the use of biosimilars and how pharmacy benefit managers (PBMs) as well as payers have challenged the biosimilar market.

As part of its inquiry, the Federal Trade Commission (FTC) will demand that the 6 largest pharmacy benefit managers (PBMs) submit records and answer questions regarding their business practices.

The dysfunction with pharmacy benefit managers (PBMs) is so troublesome that the Federal Trade Commission (FTC) is currently investigating how they have driven up costs. Until May 25, the FTC is holding a public comment period on PBM practices.

Many oncologists oppose white bagging because they prefer to be able to adjust doses during a visit based on lab reports taken that day.

Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, discusses cost-saving implications of biosimilars in oncology, as well as several barriers that continue to impede their use.

Kathy Oubre, MS, chief operating officer, Pontchartrain Cancer Center, explores US adoption of biosimilars ahead of her panel discussion at the 2021 Community Oncology Conference, as well as what sessions she’s looking forward to attending.

More biosimilars are hitting the US market, but marketplace dynamics have made it difficult to take advantage of these therapies.

In the past 5 years, a community-based cancer clinic has undergone a large degree of change to achieve its goals of practice transformation and value-based care (VBC).

The clinicians and nurses at Pontchartrain Cancer Center address the education behind the clinical trials, which helps patients understand that they can have access to cutting edge therapy that they would not otherwise have access to, said Kathy W. Oubre, MS, chief operating officer at Pontchartrain Cancer Center. Kathy Oubre is additionally scheduled to speak at the Community Oncology Alliance Virtual Meeting, which runs from April 23-24, 2020.

Developing an expansive program to meet the needs of all of our patients, at all education levels, is 1 of the biggest challenges we face at Pontchartrain Cancer Center, said Kathy W. Oubre, MS, chief operating officer at Pontchartrain Cancer Center. Kathy Oubre is additionally scheduled to speak at the Community Oncology Alliance Virtual Meeting, which runs from April 23-24, 2020.